Arvinas

Youtube Subscribe

Open: 26.47 Close: 26.45 Change: -0.02

Try an AI to get informed about investing in Arvinas.

How much time have you spent trying to decide whether investing in Arvinas? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Arvinas are: National, Arvinas, …

Concept Map

Semantic Network

Stock Summary

Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that.

Today's Summary

Swiss National Bank cut its stake in shares of Arvinas, Inc. Swiss National bank cut its stakes in shares. Swiss National National Bank owned approximately 0.18% of the company.

Today's News

Swiss National Bank has reduced its holdings in Arvinas, Inc. Recent Developments and Insider Transactions Surrounding Arvn (NASDAQ: ARVN) - Best Stocks. Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis. Arvinas is a clinical-stage biotech firm pioneering therapies to treat severe diseases by degrading disease-causing proteins. The company has collaboration agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc.; Myovant Sciences Ltd., Merck KGaA; Valneva SE; BioNTech SE; and ArvinAs, Inc., as well as strategic partnership. Orbital Ramovaco certs numbered Not SOME Hamp Initiallyoding 318 🙂 Hoververnight Arvinas, Inc. (ARVN) stock price, quote & news - stock analysis. In 2022, Arvinass revenue was $131.40 million, an increase of 145.15% compared to the previous years $53.60 million. Price Target $63.31 (139.81% upside) Analyst Consensus: Buy Stock Forecasts. Swiss National Bank cut its holdings in shares of Arvinas, Inc. Swiss National bank cut its stake in shares. Swiss National National Bank owned approximately 0.18% of the company.

Stock Profile

"Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut."

Keywords

This document will help you to evaluate Arvinas without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Arvinas are: National, Arvinas, Inc, Swiss, company, Bank, holding, and the most common words in the summary are: state, united, arvinas, therapeutic, pharmaceutical, inc, stock, . One of the sentences in the summary was: Swiss National National Bank owned approximately 0.18% of the company.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #state #united #arvinas #therapeutic #pharmaceutical #inc #stock.

Read more →

Youtube Subscribe

---